CR 3294

Drug Profile

CR 3294

Alternative Names: CR3294

Latest Information Update: 22 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Anti-inflammatories; Benzamidines; Small molecules
  • Mechanism of Action Metalloprotease inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diarrhoea; Inflammatory bowel diseases; Mucositis

Most Recent Events

  • 22 Sep 2017 No recent reports on development identified - Phase-II for Inflammatory bowel disease, Mucositis (Chemotherapy-induced) and Diarrhoea (Chemotherapy-induced) in Italy (unspecified route)
  • 01 Nov 2014 Phase II development for Diarrhoea, Inflammatory bowel disease and Mucositis is ongoing in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top